NCT07265544 Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
| NCT ID | NCT07265544 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Condition | Liver Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2023-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily signed the informed consent form; 2. No restrictions on age and gender; 3. Patients diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver in accordance with the "Guidelines for the Diagnosis and Treatment of Focal Liver Lesions (2014 Edition)" and the "Guidelines for the Diagnosis and Treatment of Hemangiomas and Vascular Malformations (2019 Edition)"; 4. Patients with hepatic hemangioma, focal nodular hyperplasia of the liver, fatty liver, HBV infection, liver fibrosis, and cirrhosis who clinically require liver surgery or liver biopsy. Exclusion Criteria: 1. Individuals with concurrent infections such as HIV will be excluded. 2. Patients with coagulation system disorders, such as hemophilia or idiopathic thrombocytopenic purpura, will not be included. 3. Those with severe underlying diseases that affect the body's immune status will be excluded. 4. Individuals whom the investigator deems unsuitable for participation in this study will be excluded.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07265544 clinical trial?
This trial is open to participants of all sexes, studying Liver Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07265544 currently recruiting?
Yes, NCT07265544 is actively recruiting participants. Contact the research team at yongyinli@foxmail.com for enrollment information.
Where is the NCT07265544 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07265544 clinical trial?
NCT07265544 is sponsored by Nanfang Hospital, Southern Medical University. The trial plans to enroll 240 participants.